FeesSafety
Pluang+

Immutep reports 81.1% 12-month disease-free survival in soft tissue sarcoma Phase II trial

Company Fundamentals
19 Nov 2026, 02:12 WIB
GlobeNewsWire
View Source
Bullish
Immutep reports 81.1% 12-month disease-free survival in soft tissue sarcoma Phase II trial

Immutep Limited announced encouraging results from its EFTISARC-NEO Phase II trial for resectable soft tissue sarcoma, showing a 12-month disease-free survival (DFS) rate of 81.1%. The trial combined eftilagimod alfa (efti) with pembrolizumab and radiotherapy before surgery. Higher post-treatment tumor-infiltrating lymphocytes and fibrosis levels were linked to better survival outcomes. Immutep plans to advance efti into a registration-directed clinical trial in 2027, aiming to improve treatment options for high-risk soft tissue sarcoma patients.

Immutep's EFTISARC-NEO Phase II trial results provide context for health sector performance. For readers following health stocks, here is Pluang's market snapshot as of Nov 19, 2026 05:41 WIB: Out of 150 priced US health-sector stocks, 53 rose and 95 fell. Notable movers include HUM at USD 385.00 with a -13.18% change, WGS at USD 52.09 with +10.15%, and UNH at USD 350.55 with -10.04%.

More News

Micron's strong growth and rising stock price hint at a possible future stock split.

Micron's strong growth and rising stock price hint at a possible future stock split.

Micron Technology is showing strong financial growth, driven by its crucial role in AI infrastructure and multiyear deals with key tech companies. The company recently beat revenue expectations with a 379% year-over-year increase and projects even be...

Company Fundamentals
Bullish
1 hour ago
FDA approves Livsayis™, first siRNA therapy for generalized myasthenia gravis, offering new treatment option.

FDA approves Livsayis™, first siRNA therapy for generalized myasthenia gravis, offering new treatment option.

The FDA has approved Livsayis™ (cemdisiran), the first and only siRNA therapy for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody-positive. This subcutaneous treatment, administered four times a year, targ...

Market News
Bullish
1 hour ago
Elauwit reports 66% growth in monthly recurring revenue to $539K, cutting expenses and expanding managed Wi-Fi networks.

Elauwit reports 66% growth in monthly recurring revenue to $539K, cutting expenses and expanding managed Wi-Fi networks.

Elauwit announced a 66% year-over-year increase in monthly recurring revenue to $539,000 by the end of Q3 2026, driven by long-term contracts for managed Wi-Fi in apartment communities. The company also reduced operating expenses by 19% sequentially ...

Company Fundamentals
Bullish
1 hour ago
Montauk Renewables delays capital spending, seeks credit amendments amid operational challenges.

Montauk Renewables delays capital spending, seeks credit amendments amid operational challenges.

Montauk Renewables deferred up to $120 million in capital spending and is negotiating credit facility amendments due to operational delays at its North Carolina swine waste project. These delays have created short-term risks for debt covenants, requi...

Company Fundamentals
Neutral
1 hour ago
Palantir's revenue soars past $2B, outpacing UiPath's slower, seasonal growth in AI software sales.

Palantir's revenue soars past $2B, outpacing UiPath's slower, seasonal growth in AI software sales.

Palantir Technologies has shown rapid quarter-over-quarter revenue growth, reaching $2.3 billion in Q3 2026, driven by strong commercial adoption of its AI platform and expansion beyond government contracts. In contrast, UiPath's revenue growth is mo...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App